comparemela.com

Page 6 - Live On Air News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

New yorkUnited statesSaadz usmaniChris ryanLive on airMyeloma serviceMemorial sloan kettering cancer centerOnclive on airApple podcastsGoogle podcastsAmazon musicFda approval of cilta celPatients with relapsed refractory multiple myeloma

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Rhode islandUnited statesBrown universityUniversity of california san franciscoAshling wahnerStephaniel graffKellye mccannReshmal mahtaniUniversity of californiaMiami cancer instituteCancer infusion servicesBreast oncology at lifespan cancer instituteDivision of hematologyHelen diller family comprehensive cancer centerBreast medical oncology at baptist health wellnessLive on air

FDA Approval Insights: Ponatinib in Ph+ ALL

Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.

United statesElias jabbourCourtney flahertyUniversity of texas md anderson cancer centerDivision of cancer medicineDepartment of leukemiaLive on airCancer medicineCancer centerOnclive on airApple podcastsGoogle podcastsAmazon musicFda approval of ponatinibPatients with ph positive allPhallcon trial

Schmid Summarizes Updates in HER2-Positive Breast Cancer Management

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

City ofUnited kingdomSan antonioUnited statesMegan hollaschPeter schmidLive on airCancer medicineExperimental cancer medicineBarts cancer instituteQueen mary universityBarts breast cancer centreAntonio breast cancer symposiumOnclive on airApple podcastsGoogle podcasts

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.

United statesCaroline seymourAndrewj wagnerDana faber cancer instituteHarvard medical schoolLive on airAmbulatory oncologyOnclive on airApple podcastsGoogle podcastsAmazon musicPatients with pecomaAmpect trial

vimarsana © 2020. All Rights Reserved.